Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

63.36
+1.021.64%
Post-market: 63.360.00000.00%16:49 EST
Volume:1.07M
Turnover:67.35M
Market Cap:7.75B
PE:-10.03
High:63.68
Open:62.21
Low:61.58
Close:62.34
52wk High:70.98
52wk Low:29.31
Shares:122.26M
Float Shares:119.09M
Volume Ratio:0.65
T/O Rate:0.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.3179
EPS(LYR):-5.2646
ROE:-572.15%
ROA:-24.93%
PB:-14.87
PE(LYR):-12.04

Loading ...

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

GlobeNewswire
·
Yesterday

EVP and Chief Commercial Officer Andrew Callos Reports Disposal of Cytokinetics Incorporated Common Shares

Reuters
·
Feb 06

Truist Raises Price Target on Cytokinetics to $92 From $84, Keeps Buy Rating

MT Newswires Live
·
Feb 03

Cytokinetics Is Maintained at Buy by Truist Securities

Dow Jones
·
Feb 03

Cytokinetics price target raised to $92 from $84 at Truist

TIPRANKS
·
Feb 03

Cytokinetics Inc : Truist Securities Raises Target Price to $92 From $84

THOMSON REUTERS
·
Feb 03

Top Cytokinetics Executive Just Cashed Out in a Notable Insider Move

TIPRANKS
·
Feb 03

Cytokinetics EVP and Chief Commercial Officer Andrew Callos Reports Disposal of Common Shares

Reuters
·
Feb 03

Cytokinetics Coverage Assumed by Barclays at Overweight

Dow Jones
·
Jan 28

Cytokinetics assumed with an Overweight at Barclays

TIPRANKS
·
Jan 28

Cytokinetics, Olympic Medalist McLaughlin-Levrone team up for awareness for HCM

TIPRANKS
·
Jan 27

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

GlobeNewswire
·
Jan 27

Cytokinetics Announces Myqorzo™ (Aficamten) NOW Available in the U.S. for the Treatment of Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

THOMSON REUTERS
·
Jan 27

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

GlobeNewswire
·
Jan 27

Do Cytokinetics’ (CYTK) New-Hire Equity Grants Reveal a Deeper Shift in Its Talent Strategy?

Simply Wall St.
·
Jan 23

RBC Capital Reaffirms Their Buy Rating on Cytokinetics (CYTK)

TIPRANKS
·
Jan 23

Cytokinetics Price Target Maintained With a $95.00/Share by RBC Capital

Dow Jones
·
Jan 21

B. Riley Raises Price Target on Cytokinetics to $108 From $90, Keeps Buy Rating

MT Newswires Live
·
Jan 21

Cytokinetics price target raised to $108 from $90 at B. Riley

TIPRANKS
·
Jan 21

BRIEF-Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Jan 21